ОНКОЛОГИЧЕСКИЕ РЕЗУЛЬТАТЫ РАДИКАЛЬНОГО ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ У ПАЦИЕНТОВ С МЕСТНО-РАСПРОСТРАНЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/1726-9776-2009-5-3-29-34
Аннотация
Рассмотрена и доказана эффективность применения метода радикальной простатэктомии при лечении больных местно-распространенным раком предстательной железы как в качестве монотерапии, так и как компонента мультимодальной терапии.
Об авторах
О. Б. Лоран
Кафедра урологии и хирургической андрологии РМАПО, Москва
Россия
Россия
Е. И. Велиев
Кафедра урологии и хирургической андрологии РМАПО, Москва
Россия
Россия
С. В. Котов
Кафедра урологии и хирургической андрологии РМАПО, Москва
Россия
Россия
Список литературы
1. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68—80.
2. Schelin S., Madsen M., Palmqvist E. et al. Long-term follow-up after triple treatment of prostate cancer stage pT3. Scand J Urol Nephrol 2009;43(3):186—91.
3. Zincke H., Bergstralh E.J., Blute M.L. et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 1994;12(11):2254—63.
4. Palapattu G.S., Allaf M.E., Trock B.J. et al. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of longterm followup. J Urol 2004;172:1860—4.
5. Bolla M., Gonzalez D., Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295—300.
6. Pilepich M.V., Caplan R., Byhardt R.W. et al. Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG protocol 85—31. J Clin Oncol 1997;15:1013—21.
7. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103—8.
8. Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. Engl J Med 1999;341(24):1781—8.
9. Da Pozzo L.F., Cozzarini C., Briganti A. et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy. The positive impact of adjuvant radiotherapy. Eur Urol 2009;55(5):1003—11.
10. Hsu C.Y., Joniau S., Oyen R. et al. Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. Asian J Androl 2009;11(1):131—7.
11. Freedland S.J., Partin A.W., Humphreys E.B. et al. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109(7):1273—8.
12. Hsu C.Y., Joniau S., Oyen R. et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007;51(1):121—8; discussion 128—9.
13. Van Poppel H., Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008;53(2):253—9.
14. Bader P., Burkhard F.C., Markwalder R., Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849—54.
15. Briganti A., Karnes J.R., Da Pozzo L.F. et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a twoinstitution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55:261—70.
16. Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54:344—52.
17. Xylinas E., Drouin S.J., Comparator E. et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU Int 2009;103(9):1173—8.
18. Lowe B.A., Lieberman S.F. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997;158(4):1452—6.
19. Yamada A.H., Lieskovsky G., Petrovich Z. et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994;17(4):277—85.
20. Van der Ouden D., Hop W.C.J., Schroder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392—7.
21. Martinez de la Riva S.I., Lopez-Tomasety J.B., Dominguez R.M. et al. Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up. Arch Esp Urol 2004;57:679—92.
22. Ward J.F., Slezak J.M., Blute M.L. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95: 751—6.
Рецензия
Для цитирования:
Лоран О.Б., Велиев Е.И., Котов С.В. ОНКОЛОГИЧЕСКИЕ РЕЗУЛЬТАТЫ РАДИКАЛЬНОГО ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ У ПАЦИЕНТОВ С МЕСТНО-РАСПРОСТРАНЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2009;5(3):29-34. https://doi.org/10.17650/1726-9776-2009-5-3-29-34
For citation:
Loran O.B., Veliyev E.I., Kotov S.V. ONCOLOGICAL RESULTS OF RADICAL SURGICAL TREATMENT IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER. Cancer Urology. 2009;5(3):29-34. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-3-29-34
Просмотров:
816
Послать статью по эл. почте 
